1. Home
  2. EQBK vs ANNX Comparison

EQBK vs ANNX Comparison

Compare EQBK & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

HOLD

Current Price

$50.43

Market Cap

993.2M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.39

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQBK
ANNX
Founded
2002
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
993.2M
812.7M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
EQBK
ANNX
Price
$50.43
$5.39
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
$51.33
$16.50
AVG Volume (30 Days)
161.8K
4.4M
Earning Date
04-14-2026
05-11-2026
Dividend Yield
1.59%
N/A
EPS Growth
N/A
N/A
EPS
0.80
N/A
Revenue
N/A
N/A
Revenue This Year
$74.58
N/A
Revenue Next Year
$5.11
$16,320.74
P/E Ratio
$62.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.04
$2.03
52 Week High
$51.73
$7.18

Technical Indicators

Market Signals
Indicator
EQBK
ANNX
Relative Strength Index (RSI) 61.80 47.18
Support Level $43.99 $4.66
Resistance Level $51.48 $5.65
Average True Range (ATR) 1.33 0.55
MACD 0.12 -0.04
Stochastic Oscillator 73.02 28.70

Price Performance

Historical Comparison
EQBK
ANNX

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: